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We found a virulent closely related clone (Panton-
Valentine leukocidin–positive, SCCmec V:ST59) of methi-
cillin-resistant  Staphylococcus aureus in inpatients and
outpatients in Taiwan. The isolates were found mostly in
wounds but were also detected in blood, ear, respiratory,
and other specimens; all were susceptible to ciprofloxacin,
gentamicin, and trimethoprim-sulfamethoxazole. 
A
lthough most methicillin-resistant Staphylococcus
aureus (MRSA) illness and death are associated with
healthcare facilities (H-MRSA), isolates from community-
associated MRSA (C-MRSA) infections have been
obtained with increasing frequency in the last few years in
different countries, including Taiwan (1–5). The changing
epidemiology of MRSA has become an important public
health concern worldwide (1,4). MRSA arises when S.
aureus organisms acquire a large mobile genetic element
called staphylococcal cassette chromosome mec
(SCCmec) (6). Most H-MRSA strains possess either
SCCmec II or III; most C-MRSA strains possess SCCmec
IV (7–9). Recently, a novel type V SCCmec type was char-
acterized and found in a C-MRSA isolate from Australia
(10). With the exception of variable resistance to erythro-
mycin, C-MRSA strains are generally susceptible to other
non-β-lactam antimicrobial agents, in contrast to most H-
MRSA, which are typically resistant to many of the non-β-
lactam agents (1,4,9). Another characteristic of C-MRSA
is the production of Panton-Valentine leukocidin (PVL), an
extracelluar cytotoxin involved in primary skin infections
and pneumonia (2–4).
We conducted a study to characterize the molecular epi-
demiology of selected MRSA isolates from the Taiwan
Surveillance of Antimicrobial Resistance (TSAR), a
national surveillance program of inpatient and outpatient
clinical isolates in Taiwan (11). We describe the finding of
a virulent closely related clone of MRSA and its preva-
lence in Taiwan.
The Study
A total of 398 and 865 nonduplicate S. aureus isolates
were collected from March to May 2000 from 21 hospitals
and from July to September 2002 from 26 hospitals,
respectively, as part of the TSAR collection (11). The pro-
portions of isolates for the 2 years were similar for outpa-
tients (27.5% in 2000 and 28.9% in 2002); the rest of the
isolates were from inpatients. The most common specimen
type was wound, which accounted for 35.4% and 49.2% of
all  S. aureus isolates in 2000 and 2002, respectively.
Antimicrobial susceptibility was determined on the basis
of results of MICs obtained from a broth microdilution
method, following the guidelines of the National
Committee for Clinical Laboratory Standards (12) by
using custom-designed Sensititre plates (Trek Diagnostics,
East Essex, United Kingdom). Overall, MRSA accounted
for 238 (59.8%) of 398 S. aureus isolates in 2000 and 475
(54.9%) of 865 S. aureus isolates in 2002.
To obtain an overall understanding of MRSA through-
out Taiwan, we first chose 80 MRSA isolates (68 inpatient
and 12 outpatient isolates) collected in 2002 from 4 hospi-
tals located in the north, middle, south, and east regions of
Taiwan. Pulsed-field gel electrophoresis was performed
according to a published protocol (9), and pulsotypes were
assigned to clusters of isolates with >80% similarity from
the dendrograms. SCCmec typing and PVL gene detection
were performed according to published protocols (7,8,10).
Multilocus sequence typing (MLST) was performed on
randomly selected strains from major pulsotypes, and the
sequence type (ST) was assigned by using the MLST data-
base (http://www.mlst.net) (13). Three major clusters (pul-
sotypes) were found, including 47 (58.8%) pulsotype A, 7
(8.8%) pulsotype B, and 18 (22.5%) pulsotype C (online
Appendix Figure 1, available from http://www.cdc.gov/
ncidod/EID/vol11no11/05-0367_app1.htm). All 47 pulso-
type Aisolates had SCCmec III; 4 isolates tested by MLST
had ST239. In addition to being resistant to clindamycin
(94%), erythromycin (100%), and tetracycline (100%), all
pulsotype A isolates were resistant to ciprofloxacin (CIP),
gentamicin (GEN), and trimethoprim/sulfamethoxazole
(SXT). The 7 pulsotype B isolates possessed SCCmec IV
but were not of the 4 known IV subtypes (IV not a–d); all
were CIP- and SXT-susceptible but GEN-resistant.
Seventeen of the 18 isolates in pulsotype C possessed
SCCmec V; the other had SCCmec IVa; all 18 were
CIP/GEN/SXT-susceptible. Of the 10 isolates tested by
MLST from pulsotype B (3 isolates) and pulsotype C
(7 isolates), all had ST59. Only pulsotype C isolates were
PVL-positive. 
Because we found a large percentage (21.3%, 17/80) of
SCCmec  V:ST59, PVL-positive clones, we selected an
additional 69 CIP/GEN/SXT-susceptible MRSA isolates
(25 from 2000, 44 from 2002) to determine what portion of
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sive care unit (ICU) and non-ICU inpatients, plus outpa-
tients from 15 hospitals in 2000 and 21 hospitals in 2002
(excluding the 4 hospitals already tested). Fifteen (60%) of
the 25 isolates from 2000 and 32 (72.7%) of the 44 isolates
from 2002 belonged to pulsotype C, had SCCmec V, and
were PVL-positive. Of the 4 isolates characterized by
MLST, 2 were ST59, 1 was ST388, and 1 was a new ST;
the last 2 isolates differed from ST59 by 1 nt each in gmk
and arcC genes, respectively.
When the 2 groups of isolates were combined, a total of
90 CIP/GEN/SXT-susceptible MRSAwere studied (online
Appendix Figure 2, available from http://www.cdc.gov/
ncidod/EID/vol11no11/05-0367_app2.htm). These isolates
were mostly resistant to clindamycin (89%), erythromycin
(92%), and tetracycline (82%). Of these 90 isolates, 68
(75.6%) were PVL-positive and belonged to same pulso-
type C; 64 (71.1%) had SCCmec V. MLST performed on
12 isolates found 10 to be ST59; the other 2 (ST338 and
the new ST) are closely related to ST59. Forty-eight of
these 64 isolates were from wounds (75%), but isolates
were also found in respiratory (6 isolates), ear (3 isolates),
blood (2 isolates), urine (2 isolates), and catheter and other
body site (3 isolates) specimens. Only half (32 isolates)
were from outpatients; the rest were from ICU (10 isolates)
and non-ICU (22 isolates) inpatients. Two ICU isolates
were from hospital-acquired infections. Because 189
(26.5%) of the 713 MRSAisolates from the 2000 and 2002
collections were CIP/GEN/SXT-susceptible, and because
64 (71.1%) of the 90 CIP/GEN/SXT-susceptible MRSA
we studied were PVL-positive, SCCmec V:ST59, and
belonged to pulsotype C, an estimated 18.8% (26.5% ×
0.711 = 18.8%) of MRSA isolates in Taiwan could be this
closely related virulent clone. 
The reason for the high prevalence of this virulent clone
(pulsotype C:ST59, SCCmec V, PVL-positive) of MRSA
in Taiwan in both inpatients and outpatients is not known.
Data on the prevalence of SCCmec V are still limited, and
ST59 has been described infrequently. A recent longitudi-
nal study of MRSA isolates in the San Francisco area
found that the ST59-SCCmec IV has increased steadily
from 1999 to become 1 of the 4 major clones associated
with C-MRSA (14). 
Production of the PVL cytotoxin is considered a genet-
ic marker for C-MRSA, and although PVL-positive
MRSAhave usually been associated with skin and soft tis-
sue infections, severe and fatal infections, such as necrotiz-
ing pneumonia, have been reported (2–4). Thus, PVL may
confer an additional virulence advantage for this particular
clone of MRSAin Taiwan. Other possible explanations are
that the less resistant C-MRSA can grow faster than
multidrug-resistant H-MRSA and that SCCmec IV and V
carried by C-MRSAmay have the advantage over SCCmec
I–III carried by H-MRSA because they are smaller and
more transferable; both of these putative advantages may
contribute to their propagation (10,15). 
The close relatedness and high prevalence of this viru-
lent pathogen argue for a clonal expansion advantage of
this particular clone. Outbreaks of C-MRSA infections
caused by SCCmec IV (IVa) have been reported in several
countries (4). Since our genotyping results showed that
MRSA isolates possessing SCCmec V and PVL in Taiwan
are clonally related, we cannot rule out the possibility of
outbreaks due to this particular clone in some areas.
However, our isolates came from multiple hospitals
throughout the 4 geographic regions of Taiwan. Our data
also showed that this particular clone was already present
in 2000. In addition, this particular clone was found not
only in outpatients but also in ICU and non-ICU inpatients,
including in hospital-acquired infections. These findings
indicate that this clone has migrated into the hospital envi-
ronment; moreover, it can cause more severe infections, as
shown by its presence in blood, respiratory, ear, and other
specimens. 
Conclusions
Our analysis of MRSA isolates collected in 2000 and
2002 indicated that a virulent clone of MRSA (pulsotype
C:ST59, SCCmec V and PVL-positive), which caused
wound infections primarily but also other potentially more
serious infections, is highly prevalent in Taiwan inpatient
and outpatient settings. Recognition of this clone can be
facilitated by its antimicrobial susceptibility profile.
Because the resistance pattern of these isolates differs from
that of traditional H-MRSA strains, the antimicrobial sus-
ceptibility profile has important implications for treatment.
Understanding the roles these strains play in MRSA epi-
demiology helps physicians choose the most appropriate
treatment. Prompt and judicious management and infec-
tion control measures should help deter further spread of
this virulent pathogen.
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